#United States #New York #Securities Fraud #Pomerantz LLP #Axogen Inc.

Pomerantz Law Firm Probes Claims Against Axogen, Inc.

Pomerantz LLP, a well-respected law firm known for its expertise in corporate and securities litigation, has initiated an investigation concerning claims made by shareholders of Axogen, Inc. (NASDAQ: AXGN). Investors are encouraged to reach out to Danielle Peyton via email or phone for further information on how to participate in the investigation.

The inquiries stem from allegations regarding potential securities fraud and other illegal business practices allegedly engaged in by Axogen and certain of its officers and/or directors. Shareholders who may have suffered losses due to these actions are urged to explore their options for joining a class action lawsuit aimed at seeking justice for their grievances.

Recent Developments at Axogen

This investigation comes in light of significant events impacting Axogen's market performance. On August 25, 2025, the company announced through a press release that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for the Avance® Nerve Graft. The new goal date is set for December 5, 2025, which represents a three-month delay from the previous deadline.

Following this announcement, there was an immediate adverse reaction from the market. Axogen’s stock price decreased by $1.47 per share, a drop of approximately 9.04%, closing at $14.79 per share on the day of the disclosure. Such a decline raises questions about the company's transparency and the impact of its disclosures on shareholders.

About Pomerantz LLP

Founded over 85 years ago by Abraham L. Pomerantz, often referred to as the dean of the class action bar, Pomerantz LLP has established itself as a leader in the field of securities class actions. The firm operates from multiple global hubs including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, offering expert legal representation to clients affected by corporate misconduct and securities fraud.

The firm aims to safeguard the rights of individuals and investors who have fallen victim to unfair business practices, recovering significant damages for clients across various cases. With an established history of successful litigation outcomes, Pomerantz brings an unparalleled depth of knowledge to the ongoing investigation into Axogen.

Potential investors and stakeholders monitoring this situation are reminded of the importance of legal representation in order to navigate the complexities often associated with such legal actions. As the investigation unfolds, further updates are expected, providing clarity on the future implications for Axogen and its shareholders.

For those interested in pursuing their claims, contact information is provided below:

• - Contact Person: Danielle Peyton
• - Email: [email protected]
• - Phone Number: 646-581-9980, ext. 7980

Investors are encouraged to stay informed as more information becomes available about this developing story and the actions taken by Axogen in response to the ongoing scrutiny.